This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AngioDynamics (ANGO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) closed the most recent trading day at $8.76, moving -1.35% from the previous trading session.
AngioDynamics (ANGO) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) closed at $8.58 in the latest trading session, marking no change from the prior day.
AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment
by Zacks Equity Research
The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimize blood loss via blood recirculation.
AngioDynamics (ANGO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, AngioDynamics (ANGO) closed at $8.34, marking a +1.46% move from the previous day.
AngioDynamics (ANGO) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in fourth-quarter fiscal 2023.
AngioDynamics (ANGO) Lags Q4 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -33.33% and 0.37%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AngioDynamics' (ANGO) fiscal fourth quarter's top line is likely to have been driven by strong demand for its products.
AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AngioDynamics (ANGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cintas (CTAS) to Post Q4 Earnings: Will Cost Woes Mar Results?
by Zacks Equity Research
Cintas' (CTAS) Q4 performance is likely to have been hurt by rising costs. However, higher volumes and prices within the Uniform Rental and Facility Services unit are likely to have aided the same.
Simulations Plus (SLP) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Simulations Plus' (SLP) third-quarter performance is likely to have gained from the healthy adoption of its solutions across various verticals amid continued macroeconomic weakness.
Are Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?
by Zacks Equity Research
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
Merit Medical (MMSI) Expands Suite via Buyouts, Revises FY23 View
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its portfolio is expected to significantly enhance patient outcomes.
New Strong Sell Stocks for May 18th
by Zacks Equity Research
ANGO, FPAY and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2023.
Zacks.com featured highlights include Dutch Bros, Chegg, Impinj and AngioDynamics
by Zacks Equity Research
Dutch Bros, Chegg, Impinj and AngioDynamics are part of the Zacks Screen of the Week article.
Is the Options Market Predicting a Spike in AngioDynamics (ANGO) Stock?
by Zacks Equity Research
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
Sell These 4 Toxic Stocks to Prevent Portfolio Losses
by Lavina Shahu
The basic understanding of toxic stocks can help investors avoid huge losses and derive maximum benefit from their portfolios. Some toxic stocks that investors may consider dumping are BROS, CHGG, PI and ANGO.
Zacks.com featured highlights include AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva
by Zacks Equity Research
AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva are part of the Zacks Screen of the Week article.
4 Toxic Stocks That Are Detrimental to Your Portfolio's Health
by Lavina Shahu
Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.
Implied Volatility Surging for AngioDynamics (ANGO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
AngioDynamics (ANGO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 2.28%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical Systems Inc. (KRMD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 20% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?
by Zacks Equity Research
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.
AngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 200% and 1.65%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?